SAB Biotherapeutics Inc. (NASDAQ: SABS) announced additional Phase 1 data for its drug candidate SAB-142 in adult patients with established ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE